Endra
ENDRA Life Sciences (NASDAQ: NDRA) commercializes TAEUS®, a CE-marked thermoacoustic-ultrasound device that non-invasively measures liver fat for hospitals, hepatology clinics, and pharma trial sponsors in Europe as a lower-cost alternative to MRI.
- Company typePublic
- Founded2007
- HeadquartersAnn Arbor, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Endra does
ENDRA Life Sciences Inc. (NASDAQ: NDRA) is a public medical-technology company headquartered in Ann Arbor, Michigan, founded in 2007. The company's commercial focus is its CE-marked TAEUS® (Thermo-Acoustic Enhanced UltraSound) platform, which combines radio-frequency stimulation with conventional B-mode ultrasound to non-invasively quantify hepatic steatosis. Multi-site clinical validation in 64 patients demonstrated r=0.90 correlation to MRI-PDFF (the imaging gold standard) and an intraclass correlation coefficient of 0.89, positioning TAEUS as a non-invasive, point-of-care alternative to liver biopsy and MRI at roughly 50x lower cost per scan. A legacy product, the Nexus 128 fully 3D photoacoustic imaging system, continues to serve laboratory research customers. ENDRA holds ISO 13485:2016 certification (BSI, valid 2025-2028) and a CE mark for European sale but is not FDA-approved for the U.S. market.
The business model is a hardware-plus-software sale of TAEUS devices to hospitals, hepatology/gastroenterology clinics, and pharmaceutical companies conducting NAFLD/NASH and obesity-drug clinical trials, with distribution supported by a strategic partnership with GE Healthcare and direct enterprise field sales. The company reports only one named commercial installation to date — King's College Hospital in London (February 2024) — alongside several research/validation collaborations with academic medical centers (UPMC, Medical College of Wisconsin, Centre Hospitalier Universitaire d'Angers, Rocky Vista University). In October 2025, ENDRA pivoted a portion of its capital structure toward a digital asset treasury managed by Arca Investment Management, and in March 2026 its board initiated a strategic alternatives review, followed by a June 2026 announcement of a merger with Noble Africa LLC (an ASP Isotopes subsidiary) under which ENDRA shareholders would own approximately 3% of the combined entity. As of Q1 2026 the company reported just $356,000 of cash, $2.4M of digital assets, and a market capitalization of approximately $4M, and in April 2026 received a Nasdaq delisting notice for non-compliance with the minimum stockholders' equity requirement.
Endra firmographics
Firmographics- Name
- Endra
- Legal name
- ENDRA Life Sciences Inc.
- Website
- https://endrainc.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ENDRA Life Sciences (NASDAQ: NDRA) commercializes TAEUS®, a CE-marked thermoacoustic-ultrasound device that non-invasively measures liver fat for hospitals, hepatology clinics, and pharma trial sponsors in Europe as a lower-cost alternative to MRI.
- Ownership category
- akta.pro rank
Endra industry classification
Industry- Product category
- Medical Imaging Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ultrasound & Echography Systems (HLAHABAD)
Keywords
Where Endra is headquartered
LocationHeadquarters
- HQ city
- Ann Arbor
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Endra business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- TAEUS Device Sales: ENDRA generates revenue from the sale of TAEUS medical devices to healthcare providers. The device is sold as hardware that pairs with existing B-mode ultrasound machines, with proprietary software for tissue analysis. CE-marked for commercial sale in Europe.
- Digital Asset Treasury: In 2025, ENDRA announced a digital asset treasury strategy managed by Arca Investment Management to acquire cryptocurrencies and generate yield from digital assets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | TAEUS Liver Device - Enterprise medical device pricing |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Endra product offering
Product offeringCore offering
ENDRA Life Sciences develops and commercializes TAEUS (Thermo-Acoustic Enhanced UltraSound), a CE-marked medical device that pairs with existing B-mode ultrasound machines to non-invasively measure liver fat content by combining radio frequency stimulation with ultrasound detection. The device delivers MRI-level accuracy (r=0.90 correlation to MRI-PDFF) at approximately 50x lower cost than MRI, producing point-of-care results in under a minute for NAFLD/MASH diagnosis and monitoring. The company also maintains the Nexus 128, a fully 3D photoacoustic imaging system for laboratory research applications.
Product overview
ENDRA Life Sciences offers a focused portfolio of two distinct products built on thermo-acoustic and photo-acoustic ultrasound technologies. The core commercial product is TAEUS® (Thermo-Acoustic Enhanced UltraSound), a CE-marked clinical device for non-invasive liver fat measurement that pairs with conventional B-mode ultrasound machines and targets the MASLD/MASH diagnostic market at a fraction of MRI cost. The legacy Nexus 128 is a research-only 3D photoacoustic imaging system that preceded TAEUS and served laboratory researchers. TAEUS is the primary focus for clinical commercialization, while Nexus 128 represents the foundational research platform from which TAEUS technology was derived.
Differentiator
Problem solved
Functional benefit
Brands
- TAEUS®: Thermo-Acoustic Enhanced UltraSound device for liver disease detection - a proprietary technology combining radio frequency and ultrasound to measure fat in the liver at 50x lower cost than MRI.
- Nexus 128
Products and services
- TAEUS (Thermo-Acoustic Enhanced UltraSound) Liver Device CE-marked clinical medical device that combines radio frequency stimulation with ultrasound detection to non-invasively quantify liver fat content. Pairs with existing B-mode ultrasound machines, delivers results in under a minute at the point of care, and demonstrates r=0.90 correlation to the MRI-PDFF gold standard at approximately 50x lower cost than MRI. Targeted at hospitals, hepatology clinics, pharmaceutical trial sponsors and academic medical centers for NAFLD/MASLD/MASH diagnosis and monitoring.
- Nexus 128 Photoacoustic Imaging System First commercially available fully 3D photoacoustic imaging system for laboratory research, providing increased sensitivity, isotropic resolution, improved image quality, faster scan times and higher throughput for imaging anatomy, physiology and labeled molecular targets using near-infrared light and a hemispherical detector array.
Quantifiable outcome
- Correlation of r=0.90 to MRI-PDFF gold standard in multi-site clinical validation with 64 patients
- +3 more outcomes
Companies that use Endra
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Endra technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Endra partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- King's College HospitalcoreFirst commercial installation of TAEUS Liver device completed in February 2024 for clinical use in liver fat monitoring.
- GE HealthcarecoreStrategic partnership with GE Healthcare as a dedicated partner for distribution and market access. GE is one of the world's foremost healthcare technology companies and global leader in medical imaging. GE Healthcare's Vice President and GM of General Imaging Ultrasound stated alignment with GE's mission of increasing access to high-quality, cost-effective healthcare.
- Rocky Vista UniversitycoreClinical partner conducting research on abdominal ultrasound and quantitative ultrasound imaging. Dr. Jing Gao serves as Associate Professor of Ultrasound and provides clinical expertise and validation support.
- UPMCcoreClinical research partner in Pittsburgh, PA for TAEUS device validation studies and clinical research collaborations.
- Centre Hospitalier Universitaire d'AngerscoreClinical partner in Angers, France for TAEUS validation studies and clinical research.
- Medical College of WisconsincoreClinical research partner in Wauwatosa, WI for TAEUS device validation and clinical studies.
- Hepion PharmaceuticalsminorIndustry and research partner for clinical collaboration on liver disease therapeutics and diagnostic monitoring.
Scale indicators10 records
Recent moves7 records
Expansion highlights5 records
Endra competitors and assessment
Company assessmentBroad incumbents
- GE Healthcare: ENDRA's distribution partner and a global leader in medical imaging, including ultrasound systems. GE Healthcare's LOGIQ/E-Series ultrasound installed base is the target hardware platform for TAEUS integration, making it both a commercial partner and a strategic incumbent that could develop competing capabilities.
- Siemens Healthineers: Major medical imaging vendor with ultrasound, MRI, and dedicated liver imaging products (e.g., LiverLab on MAGNETOM scanners). Competes with TAEUS for the liver fat quantification use case through its broader installed base and integrated imaging IT.
- Philips: Global medical imaging incumbent offering EPIQ and Affiniti ultrasound systems that compete for the same point-of-care liver imaging workflow. Philips' installed base and IntelliSpace Portal data integration are direct competitive considerations for TAEUS adoption.
- FUJIFILM Healthcare (formerly Hitachi Medical Systems): FUJIFILM Healthcare (combining Hitachi diagnostic imaging) markets ultrasound and MRI systems used in hepatology workflows. It is a broad incumbent in the same hospital imaging channels where TAEUS would be deployed.
- Canon Medical Systems: Canon Medical markets Aplio ultrasound systems and Vantage Galan MRI systems with liver imaging capabilities. As a broad imaging incumbent it competes for hospital capital budgets and clinical workflow share relevant to TAEUS.
- Hologic: Hologic has expanded into liver diagnostics through its acquisition of Biotheranostics and broader women's health/diagnostics franchise. It is a broad incumbent that could expand into NAFLD/MASH non-invasive diagnostics adjacent to TAEUS's target market.
Direct peers
- Perspectum: Perspectum offers LiverMultiScan, an MRI-based quantitative liver tissue characterization service for fat, iron, and fibrosis. It competes with TAEUS for the same NAFLD/MASH diagnostic use case but via MRI rather than ultrasound.
- Echosens: Echosens markets FibroScan, the leading non-invasive point-of-care device for liver steatosis and stiffness assessment. It is the most direct competitive alternative to TAEUS for NAFLD/MASH diagnosis and monitoring in hepatology and endocrinology workflows.
Emerging players
- Resonance Health: Specialized in MRI-based liver iron (FerriSmart) and liver fat quantification. Competes with TAEUS for NAFLD/MASH monitoring use cases via a non-invasive imaging biomarker approach, though at a different cost point and modality.
- Owlstone Medical: Owlstone Medical develops breath-based diagnostics including for liver disease. It is an emerging non-invasive alternative addressing the same NAFLD/MASH screening and monitoring use case as TAEUS, but via volatile organic compound analysis rather than imaging.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Endra social profiles
Digital presenceEndra compliance and trust
Trust signalCompliance2 records
Endra financial estimates
Financial estimateRevenue estimate
Valuation estimate
Endra leadership team
Management profileNumber of profiles
Profiles10 records
Endra subsidiaries and ownership
Company hierarchySubsidiaries1 record
Endra funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Endra M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Endra
What does Endra do?
ENDRA Life Sciences develops and commercializes TAEUS (Thermo-Acoustic Enhanced UltraSound), a CE-marked medical device that pairs with existing B-mode ultrasound machines to non-invasively measure liver fat content by combining radio frequency stimulation with ultrasound detection. The device delivers MRI-level accuracy (r=0.90 correlation to MRI-PDFF) at approximately 50x lower cost than MRI, producing point-of-care results in under a minute for NAFLD/MASH diagnosis and monitoring. The company also maintains the Nexus 128, a fully 3D photoacoustic imaging system for laboratory research applications.
Is Endra a public or private company?
Endra is a public company. It is classified as public and is currently operating.
When was Endra founded?
Endra was founded in 2007. It employs 11 to 50 people.
Where is Endra based?
Endra is headquartered in Ann Arbor, United States, in the North America region.
How does Endra make money?
Two revenue lines are on record. TAEUS Device Sales are the primary driver. The others are digital Asset Treasury.
Who are Endra's main competitors?
Broad incumbents on record are GE Healthcare, Siemens Healthineers, Philips, FUJIFILM Healthcare (formerly Hitachi Medical Systems), Canon Medical Systems and Hologic. Direct peers are Perspectum and Echosens. Emerging players are Resonance Health and Owlstone Medical.
Does Endra have an API?
No public API is recorded for Endra.
What industry is Endra in?
Endra's product category is Medical Imaging Devices. Its primary akta.pro industry code is HLAHABAD, Ultrasound & Echography Systems. Its NAICS code is 334510 and its SIC code is 3841.